secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2023-02-14T23:59:59+00:00
Accession:  0000950170-23-002698
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Pharma Q3 net loss $3.9M; cash $31.3M; pipeline advances to Phase 3
--------------------------------------------------------------------------

- Net loss $3.9M ($0.09 loss per share) vs $3.8M loss a year ago.
- Cash, equivalents and ST investments $31.3M as of Dec 31, 2022; funds operations into Q2 2024.
- GTX-104: Expects FDA Type C meeting in Q1 2023; may initiate Phase 3 safety study.
- GTX-102 PK bridging study met all primary endpoints; Phase 3 planning underway.
- GTX-101 PK study met all primary endpoints; multiple ascending dose study planned in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023002698/0000950170-23-002698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023002698/acst-20230214.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-002698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer